SASonia Albini

Sonia Albini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sonia Albini has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dystrophin Domain Composition Regulates Mechanical Resilience in Duchenne Muscular Dystrophy 

    by Laura Palmieri, Maxime Ferrand, Matteo Marcello, Ai Vu Hong, Ines Sandid, Corentin Azzoun, Jeremie Cosette, Redouane Foudil, Giulia Sautariello, Elena Battirossi, et al.

    Duchenne muscular dystrophy (DMD) is a fatal X-linked muscle disorder caused by the absence of dystrophin, resulting in progressive membrane instability, impaired force transmission, and muscle degeneration. Current adeno-associated virus (AAV)-based gene replacement strategies rely on truncated dystrophin variants due to vector cargo limitations, yet the determinants of their therapeutic efficacy remain poorly understood. Here, we investigated how dystrophin domain composition influences membrane stabilization and muscle performance by comparing micro-dystrophin (µDys) with two larger Midi-dystrophin variants generated using a dual myotropic AAV trans-splicing intein-based system. Using human DMD muscle organoids and mouse models, we show that µDys provides significant histological and functional improvement but limited protection against contraction-induced mechanical stress. In contrast, larger dystrophin variants achieved superior functional rescue, with efficacy strongly dependent on domain architecture. A membrane binding-enriched Midi-dystrophin improved sarcolemmal stability, mechanical resistance, protection of fast-twitch fibres, and restoration of dystrophin-associated protein interactions. Together, these findings demonstrate that dystrophin domain composition, rather than size alone, determines therapeutic efficacy and provide a framework for domain-guided engineering of next-generation DMD gene therapies.

  • Open Access

    A Single Lipid Nanoparticle Formulation Enables Delivery of Diverse RNA Therapeutics to Human Muscle Models of Duchenne Muscular Dystrophy

    by Paola Galbiati, Delphine Leclerc, Margaux Mombled, Ruqayya Khan, Maelle Ralu, Giorgia Bimbi, Giulia Scalisi, Kamel Mamchaoui, Francesco Saverio Tedesco, Sonia Albini, et al.

    Duchenne muscular dystrophy is a lethal neuromuscular disorder caused by the absence of dystrophin, for which no curative treatment is available. RNA based approaches have shown promising results; however, their evaluation is hindered by the lack of robust and rapid delivery methods for differentiated human muscle cells, which represent the most physiologically relevant in vitro models for assessing therapeutic strategies. Here, we establish a versatile lipid nanoparticle platform enabling efficient delivery of diverse RNA therapeutics across a range of human muscle models, including myotubes, induced pluripotent stem cell-derived myotubes, myoblasts, cardiomyocytes, and 3D engineered skeletal muscle tissues. Remarkably, a single commercially available lipid nanoparticle formulation supports delivery of cargos spanning more than 300-fold in size, from short antisense oligonucleotides (~20 nt) to complex CRISPR-based editors (up to ~6.7 kb), including Cas9 nucleases, adenine base editors, and CRISPRa systems. This enables efficient gene correction and transcriptional modulation, resulting in dystrophin restoration or compensatory utrophin upregulation in relevant Duchenne muscular dystrophy models. Together, our results establish a single lipid nanoparticle formulation as a versatile platform for RNA delivery in human muscle systems and provide a practical framework for the rapid preclinical assessment of emerging therapies for Duchenne muscular dystrophy and other neuromuscular disorders.

  • Open Access

    AI-designed AAV capsids deliver high-efficiency muscle gene transfer for low-dose therapy

    by Ai Vu Hong, Eva Petat, Laurence Suel, Jeanette Zanker, Nathalie Bourg, Abbass Jaber, Noémie Pinault, Céline Chen, Guillaume Dubreuil, Laura Palmieri, et al.

    Muscular dystrophies are debilitating genetic disorders with no curative therapies. While AAV vectors offer promise, current capsids remain limited by pre-existing immunity, high-dose-induced toxicity, and manufacturing burden. We and others recently demonstrated that cross-species myotropism can be achieved by redirecting AAV tropism toward the conserved receptor αVβ6 integrin. Here, we present an AI-guided engineering strategy that generates improved αVβ6-binding capsids by jointly optimizing sequence-structure through thermostability modelling, the use of protein language model and structure-conditioned sequence design. Screening of AI-designed variants identified lead capsids (named LICA3 and LICA4), that exhibit substantially enhanced transduction in skeletal and cardiac muscle, surpassing state-of-the-art myotropic capsids, together with strong liver-detargeting and improved manufacturability. Mechanistically, we showed that LICA3/4 efficiently engage integrin αVβ6 across species to mediate cellular entry and drive rapid redistribution from circulation to muscle fibers, resulting in increased tissue accumulation and a >100-fold enhancement in transgene expression per vector genome compared to AAV9. In a severe LGMDR3 mouse model treated systemically at a low dose (5E12 vg/kg), both variants drive saturated myofiber transduction and fully restore muscle function. These results demonstrate their clinical potential for gene therapy targeting muscle and cardiac diseases.

  • Open Access

    Author Correction: Disease exacerbation in human DMD MYOrganoids enables gene therapy evaluation and unveils persistence of fibrotic activity

    by Laura Palmieri, Giorgia Bimbi, Maxime Ferrand, Matteo Marcello, Louna Pili, Ai Vu Hong, Abbass Jaber, Riyad El-Khoury, Guy Brochier, Anne Bigot, et al.

  • Open Access

    Disease exacerbation in human DMD MYOrganoids enables gene therapy evaluation and unveils persistence of fibrotic activity

    by Laura Palmieri, Giorgia Bimbi, Maxime Ferrand, Matteo Marcello, Louna Pili, Ai Vu Hong, Abbass Jaber, Riyad El-Khoury, Guy Brochier, Anne Bigot, et al.

    Leading gene therapy approaches for Duchenne muscular dystrophy (DMD) using AAV-mediated delivery of microdystrophin (µDys) have shown partial efficacy in patients, contrasting with the favorable outcomes observed in animal models. The identification of effective therapeutic strategies could be accelerated by using human high-throughput DMD models that replicate the molecular complexity driving pathology for accurate screening. To face this challenge, we develop MYOrganoids, an engineered muscle platform derived from patient-induced pluripotent stem cells (iPSC), recapitulating critical hallmarks of DMD, such as fibrosis and muscle dysfunction. We show that co-culture of fibroblasts with iPSC-derived muscle cells during organoid generation is pivotal for functional maturation and muscle force evaluation upon eccentric contractions. Notably, incorporation of DMD fibroblasts induced phenotypic exacerbation in DMD MYOrganoids by unraveling of fibrotic signature and fatiguability through cell-contact and paracrine mechanisms. We then exploited our system to interrogate gene therapy efficacy in this severe context. Although µDys gene transfer improves muscle resistance and partially restores membrane stability, it fails to reduce profibrotic signaling. These findings highlight the persistence of fibrotic activity post-gene therapy in our system, a limitedly explored aspect in DMD models, and provide the opportunity to study mechanisms of dysregulated cellular communication and empower gene therapy efficacy.


  • Open Access

    Lysosomal damage is a therapeutic target in Duchenne muscular dystrophy

    by Abbass Jaber, Laura Palmieri, Rania Bakour, Nathalie Bourg, Ai Vu Hong, Elise Lachiver, Carinne Roudaut, Jérôme Poupiot, Sonia Albini, Daniel Stockholm, et al.

    Duchenne muscular dystrophy (DMD), a muscle degenerative disease affecting young boys, arises from the loss of dystrophin. Current gene therapy approaches aim to restore a shortened form of dystrophin (microdystrophin) via adeno-associated vector delivery. While recent clinical studies show promise, therapeutic efficacy remains incomplete, emphasizing the need for improved approaches. Here, we identified lysosomal perturbations in myofibers of patients with DMD and animal models, an overlooked mechanism of cellular damage in muscular dystrophies. These were notably marked by the up-regulation and recruitment of Galectin-3, a biomarker of lysosomal membrane permeabilization, to lysosomes, alongside alterations in lysosome number, morphology, and function. Microdystrophin therapy in Dmd mdx mice fails to fully correct these damages. However, combining it with trehalose, a lysosome-protective disaccharide, substantially improves the outcome, enhancing muscle function, myopathology, and transcriptome. These findings highlight lysosomal damage as an important pathomechanism in DMD and suggest that combining trehalose with gene therapy could enhance therapeutic efficacy.


  • Open Access

    Disease exacerbation in MYOrganoids derived from Duchenne Muscular Dystrophy iPSC reveals limitations of microdystrophin therapeutic efficacy

    by Sonia Albini, Laura Palmieri, Louna Pili, Abbass Jaber, Ai Vu Hong, Melissa Moula, Riyad El-Khoury, Guy Brochier, Anne Bigot, David Israeli, et al.

    Current gene therapy approaches for Duchenne muscular dystrophy (DMD) using AAV-mediated delivery of microdystrophin (µDys) have shown limited efficacy in patients, contrasting with the favorable outcomes observed in animal models. This discrepancy is partly due to the lack of models that replicate key pathogenic features associated with the severity of the human disease, such as fibrosis and muscle dysfunction. To tackle the translational gap, we develop a human disease model that recapitulates these critical hallmarks of DMD for a more predictive therapeutic investigation. Using a muscle engineering approach, we generate MYOrganoids from iPSC-derived muscle cells co-cultured with fibroblasts that enable functional maturation for muscle force analysis upon contractions. Incorporation of DMD fibroblasts within DMD iPSC-derived muscle cells allows phenotypic exacerbation by unraveling of fibrotic signature and fatiguability through cell-contact-dependent communication. Although µDys gene transfer partially restores muscle resistance, it fails to fully restore membrane stability and reduce profibrotic signaling. These findings highlight the persistence of fibrotic activity post-gene therapy in our human DMD system, an unparalleled aspect in existing DMD models, and provide the opportunity to explore the underlying mechanisms of dysregulated cellular communication to identify anti-fibrotic strategies empowering gene therapy efficacy.

  • Open Access

    In Silico Structural Prediction for the Generation of Novel Performant Midi-Dystrophins Based on Intein-Mediated Dual AAV Approach

    by Laura Palmieri, Maxime Ferrand, Ai Vu Hong, Isabelle Richard, Sonia Albini

    Duchenne Muscular Dystrophy (DMD) is a pediatric disorder characterized by progressive muscle degeneration and premature death, and has no current cure. The current, most promising therapeutic avenue is based on gene replacement mediated by adeno-associated viruses (AAVs) using a shortened, but still functional, version of dystrophin, known as micro-dystrophin (µDys), to fit AAV capacity. The limited improvements observed in clinical trials suggest a sub-optimal performance of µDys in the human context that could be due to the lack of key domains in the protein. Therefore, expressing larger dystrophin proteins may be necessary for a more complete correction of the disease phenotype. In this study, we developed three novel midi-dystrophin constructs using a dual-AAV approach, leveraging split-intein-based protein trans-splicing. The midi-dystrophins include additional domains compared to µDys, such as the central cytoskeleton-binding domain, nNOS and Par1b interacting domains, and a complete C-terminal region. Given the limited capacity of each AAV vector, we strategically partially reduced hinge regions while ensuring that the structural stability of the protein remains intact. We predicted the interactions between the two halves of the split midi-Dys proteins thanks to the deep learning algorithm AphaFold3. We observed strong associations between the N- and C-termini in midi-Dys 1 and 2, while a weaker interaction in midi-Dys 3 was revealed. Our subsequent experiments confirmed the efficient protein trans-splicing both in vitro and in vivo in DBA2/mdx mice of the midi-Dys 1 and 2 and not in midi-Dys 3 as expected from the structural prediction. Additionally, we demonstrated that midi-Dys 1 and 2 exhibit significant therapeutic efficacy in DBA2/mdx mice, highlighting their potential as therapeutic agents for DMD. Overall, these findings highlight the potential of deep learning-based structural modeling for the generation of intein-based dystrophin versions and pose the basis for further investigation of these new midi-dystrophins versions for clinical studies.


  • Open Access

    In Silico Structural Prediction for the Generation of Novel Performant Midi-Dystrophins Based on Intein-Mediated Dual AAV Approach

    by Laura Palmieri, Maxime Ferrand, Ai Vu Hong, Isabelle Richard, Sonia Albini

    Duchenne Muscular Dystrophy (DMD) is a pediatric disorder characterized by progressive muscle degeneration and premature death, with no cure at the moment. The currently most promising therapeutic avenue is based on gene replacement mediated by adeno-associated viruses (AAVs) using a shortened, but still functional, version of Dystrophin, known as microdystrophin (µDys), to fit AAV capacity. The limited improvements observed in clinical trials suggest a sub-optimal performance of µDys in the human context, that could be due to the lack of key domains in the protein. Therefore, expressing larger dystrophin proteins may be necessary for a more complete correction of the disease phenotype. In this study, we developed three novel Midi-Dystrophin constructs using a dual-AAV approach, leveraging split intein-based protein trans-splicing. The midi-dystrophins include additional domains compared to µDys, such as the central cytoskeleton-binding domain, nNOS and Par1b interacting domains, and a complete C-terminal region. Given the limited capacity of each AAV vector, we strategically partially reduced hinge regions while ensuring that the structural stability of the protein remains intact. We predicted the interactions between the two halves of the split Midi-Dys proteins thanks to the deep-learning algorithm AphaFold3. We observed strong associations between the N- and C-termini in Midi-Dys 1 and 2, while a weaker interaction in Midi-Dys 3 was revealed. Our subsequent experiments confirmed the efficient protein trans-splicing both in vitro and in vivo in DBA2/mdx mice of the Midi-Dys 1 and 2 and not in Midi-Dy3 as expected from the structural prediction. Additionally, we demonstrated that Midi-Dys 1 and 2 exhibit significant therapeutic efficacy in DBA2/mdx mice, highlighting their potential as therapeutic agents for DMD. Overall, these findings highlight the potential of deep learning-based structural modeling for the generation of intein-based dystrophin versions and pose the basis for further investigation of these new midi-dystrophins versions for clinical studies.


  • Open Access

    SETDB1 modulates the TGFβ response in Duchenne muscular dystrophy myotubes

    by Alice Granados, Maeva Zamperoni, Roberta Rapone, Maryline Moulin, Ekaterina Boyarchuk, Costas Bouyioukos, Laurence Del Maestro, Véronique Joliot, Elisa Negroni, Myriame Mohamed, et al.

    Overactivation of the transforming growth factor-β (TGFβ) signaling in Duchenne muscular dystrophy (DMD) is a major hallmark of disease progression, leading to fibrosis and muscle dysfunction. Here, we investigated the role of SETDB1 (SET domain, bifurcated 1), a histone lysine methyltransferase involved in muscle differentiation. Our data show that, following TGFβ induction, SETDB1 accumulates in the nuclei of healthy myotubes while being already present in the nuclei of DMD myotubes where TGFβ signaling is constitutively activated. Transcriptomics revealed that depletion of SETDB1 in DMD myotubes leads to down-regulation of TGFβ target genes coding for secreted factors involved in extracellular matrix remodeling and inflammation. Consequently, SETDB1 silencing in DMD myotubes abrogates the deleterious effect of their secretome on myoblast differentiation by impairing myoblast pro-fibrotic response. Our findings indicate that SETDB1 potentiates the TGFβ–driven fibrotic response in DMD muscles, providing an additional axis for therapeutic intervention.